|
LOC401588 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.99840144432528E-15 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62725388719309E-12 |
| Normal-vs-Stage2 |
4.62500004960731E-09 |
| Normal-vs-Stage3 |
1.11022302462516E-16 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
4.394200E-02 |
| Stage1-vs-Stage3 |
1.433630E-01 |
| Stage1-vs-Stage4 |
3.022900E-03 |
| Stage2-vs-Stage3 |
4.236500E-03 |
| Stage2-vs-Stage4 |
3.626900E-04 |
| Stage3-vs-Stage4 |
1.265210E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.44089209850063E-16 |
| Normal-vs-AfricanAmerican |
9.76820000442302E-08 |
| Normal-vs-Asian |
1.99840144432528E-15 |
| Caucasian-vs-AfricanAmerican |
3.678800E-01 |
| Caucasian-vs-Asian |
8.151800E-01 |
| AfricanAmerican-vs-Asian |
4.566000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62503344114384E-12 |
| Normal-vs-Female |
1.62736490949555E-12 |
| Male-vs-Female |
3.307000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.4432899320127E-15 |
| Normal-vs-Age(41-60Yrs) |
1.62636570877339E-12 |
| Normal-vs-Age(61-80Yrs) |
4.9960036108132E-15 |
| Normal-vs-Age(81-100Yrs) |
3.824800E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.006200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.847200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.585800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.655200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.045400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.369400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.25590000030907E-07 |
| Classical-VS-Follicular |
3.042200E-03 |
| Classical-VS-Other |
5.996400E-01 |
| Classical-VS-Normal |
5.32907051820075E-15 |
| Tall-VS-Follicular |
3.72529995740223E-09 |
| Tall-VS-Other |
5.257800E-02 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
1.617680E-02 |
| Follicular-VS-Normal |
7.56639195742537E-12 |
| Other-VS-Normal |
3.22409987596473E-10 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.64013247427874E-12 |
| Normal-vs-N1 |
1.11022302462516E-15 |
| N0-vs-N1 |
1.740580E-01 |
|
|
